TickerHumSide-by-side comparison
Gilead Sciences vs Pfizer
As of Nov 11, 2026, P/S is 6.8x for Gilead Sciences vs 2.6x for Pfizer; revenue growth is 6.5% for Gilead Sciences vs 1.3% for Pfizer; net margin is -12.5% for Gilead Sciences vs 6.3% for Pfizer; debt/equity is 1.83 for Gilead Sciences vs 0.67 for Pfizer.
What stands out
- Pfizer carries less debt relative to equity: 0.67 vs 1.83 for Gilead Sciences.
Key metrics
| Metric | GILD | PFE |
|---|---|---|
| Price | $169.73 | $29.45 |
| Market cap | $210.52B | $167.86B |
| P/E | — | 42.1x (#1) |
| P/S | 6.8x (#2) | 2.6x (#1) |
| Revenue growth | 6.5% (#1) | 1.3% (#2) |
| Operating margin | -7.6% (#1) | — |
| Net margin | -12.5% (#2) | 6.3% (#1) |
| Debt / equity | 1.83 (#2) | 0.67 (#1) |
| 1-year return | +37.5% (#1) | — |
| Research score | 45/100 (#2) | 52/100 (#1) |
Higher is better for growth, margins, one-year return and overall score; lower is better for valuation and debt ratios. Ties share a rank and missing values are excluded.
Company research
- Gilead Sciences, Inc. (GILD) — Drug Manufacturers—General
- Pfizer Inc. (PFE) — Drug Manufacturers—General